Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glaxo filling gap in HIV portfolio via licensing agreement with Hoechst/Bayer for non-nucleoside RTI.

Executive Summary

GLAXO CONTINUES HIV THERAPY IN-LICENSING STRATEGY WITH HOECHST/BAYER AGREEMENT giving Glaxo Wellcome rights to develop and market the quinoxaline class of non-nucleoside reverse transcriptase inhibitors discovered as part of a research collaboration between Hoechst Marion Roussel and Bayer. Under the Feb. 12 agreement, Glaxo will make an upfront payment to Hoechst and Bayer, make a milestone payment for the first compound to reach the market and pay royalties on any product sales. The agreement is subject to antitrust review.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS031663

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel